Proposed Models for Prediction of Mortality in Stage-I and Stage-II Gastric Cancer and 5 Years after Radical Gastrectomy
Table 2
The chi-square analysis of the connection between F–SII and clinicopathological features in Groups A and B.
Characteristics
Group A
Group B
F–SII = 0 (n = 137)
F–SII = 1 (n = 121)
F–SII = 2 (n = 57)
P value
F–SII = 0 (n = 236)
F–SII = 1 (n = 148)
F–SII = 2 (n = 56)
P value
Sex
0.420
0.120
Male
99 (41.6)
93 (39.1)
46 (19.3)
187 (55.8)
104 (31.0)
44 (13.1)
Female
38 (49.4)
28 (36.4)
11 (14.3)
49 (46.7)
44 (41.9)
12 (11.4)
Age (years)
0.224
0.024
≤60
76 (47.5)
60 (37.5)
24 (15.0)
150 (58.4)
82 (31.9)
25 (9.7)
>60
61 (39.4)
61 (39.4)
33 (21.3)
86 (47.0)
66 (36.1)
31 (16.9)
BMI
0.133
0.083
≤21.92
72 (49.7)
46 (31.7)
27 (18.6)
81 (48.2)
59 (35.1)
28 (16.7)
>21.92
48 (40.3)
52 (43.7)
19 (16.0)
155 (57.0)
89 (32.7)
28 (10.3)
Borrmann type
0.145
0.042
0
14 (70.0)
5 (25.0)
1 (5.0)
43 (71.7)
16 (26.7)
1 (1.7)
1
6 (42.9)
5 (35.7)
3 (21.4)
15 (65.2)
7 (30.4)
1 (4.3)
2
36 (48.0)
25 (33.3)
14 (18.7)
62 (48.4)
46 (35.9)
20 (15.6)
3
79 (40.7)
78 (40.2)
37 (19.1)
108 (51.4)
72 (34.3)
30 (14.3)
4
2 (16.7)
8 (66.7)
2 (16.7)
8 (42.1)
7 (36.8)
4 (21.1)
Tumor location
0.639
0.189
Upper third
13 (41.9)
14 (45.2)
4 (12.9)
20 (43.5)
20 (43.5)
6 (13.0)
Middle third
24 (42.1)
25 (43.9)
8 (14.0)
23 (43.4)
23 (43.4)
7 (13.2)
Lower and entire third
100 (44.1)
82 (36.1)
45 (19.8)
193 (56.6)
105 (30.8)
43 (12.6)
Tumor diameter (mm)
＜0.001
＜0.001
≤50
119 (51.3)
73 (31.5)
40 (17.2)
205 (60.8)
101 (30.0)
31 (9.2)
>50
18 (21.7)
48 (57.8)
17 (20.5)
31 (30.1)
47 (45.6)
25 (24.3)
Scope of gastrectomy
0.739
0.151
Proximal gastrectomy
12 (44.4)
11 (40.7)
4 (14.8)
18 (46.2)
15 (38.5)
6 (15.4)
Distal gastrectomy
105 (45.3)
85 (36.6)
42 (18.1)
194 (56.7)
106 (31.0)
42 (12.3)
Total gastrectomy
20 (35.7)
25 (44.6)
11 (19.6)
24 (40.7)
27 (45.8)
8 (13.6)
Lymph node metastasis rate (%)
0.072
0.790
0
69 (45.1)
56 (36.6)
28 (18.3)
176 (54.0)
111 (34.0)
39 (12.0)
>0 to ≤0.3
55 (48.2)
38 (33.3)
21 (18.4)
58 (53.7)
34 (31.5)
16 (14.8)
>0.3 to ≤1
13 (27.1)
27 (56.3)
8 (16.7)
2 (33.3)
3 (50.0)
1 (16.7)
pTNM stagea
0.002
＜0.001
I
53 (58.2)
29 (31.9)
9 (9.9)
117 (73.1)
38 (23.8)
5 (3.1)
II
40 (38.8)
36 (35.0)
27 (26.2)
119 (42.5)
110 (39.3)
51 (18.2)
III
44 (36.4)
56 (46.3)
21 (17.4)
-
-
-
Histological type
0.320
0.966
Well and moderately differentiated
56 (46.3)
43 (35.5)
22 (18.2)
110 (52.9)
70 (33.7)
28 (13.5)
Poorly differentiated
73 (43.5)
63 (37.5)
32 (19.0)
97 (53.9)
60 (33.3)
23 (12.8)
Others
8 (30.8)
15 (57.7)
3 (11.5)
29 (55.8)
18 (34.6)
5 (9.6)
H. pylori infection
0.983
0.781
Negative
17 (39.5)
15 (34.9)
11 (25.6)
20 (43.5)
17 (37.0)
9 (19.6)
Positive
23 (38.3)
22 (36.7)
15 (25.0)
36 (50.0)
23 (31.9)
13 (18.1)
SII: systemic immune inflammation index, F: fibrinogen. aBased on the eighth edition of the AJCC Cancer Staging Manual of the American Joint Committee on Cancer. Statistically significant P values are in bold ().
